BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22069716)

  • 1. A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines.
    Tsai LK; Pop LM; Liu X; Vitetta ES
    Toxins (Basel); 2011 Apr; 3(4):409-19. PubMed ID: 22069716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
    Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
    Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
    Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH
    Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
    Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
    Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
    Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
    Herrera L; Yarbrough S; Ghetie V; Aquino DB; Vitetta ES
    Leukemia; 2003 Feb; 17(2):334-8. PubMed ID: 12592332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
    Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
    Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia.
    Herrera L; Stanciu-Herrera C; Morgan C; Ghetie V; Vitetta ES
    Leuk Lymphoma; 2006 Nov; 47(11):2380-7. PubMed ID: 17107913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
    Herrera L; Farah RA; Pellegrini VA; Aquino DB; Sandler ES; Buchanan GR; Vitetta ES
    Leukemia; 2000 May; 14(5):853-8. PubMed ID: 10803517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.
    Schindler J; Gajavelli S; Ravandi F; Shen Y; Parekh S; Braunchweig I; Barta S; Ghetie V; Vitetta E; Verma A
    Br J Haematol; 2011 Aug; 154(4):471-6. PubMed ID: 21732928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice.
    Schnell R; Katouzi AA; Linnartz C; Schoen G; Drillich S; Hansmann ML; Schiefer D; Barth S; Zangemeister-Wittke U; Stahel RA; Diehl V; Engert A
    Int J Cancer; 1996 May; 66(4):526-31. PubMed ID: 8635869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines.
    Stanciu-Herrera C; Morgan C; Herrera L
    Leuk Res; 2008 Apr; 32(4):625-32. PubMed ID: 17706771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.
    Myers DE; Uckun FM
    Leuk Lymphoma; 1995 Jun; 18(1-2):119-22. PubMed ID: 8580813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Uckun FM; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Manivel C; Irvin JD; Myers DE; Gunther R
    Blood; 1992 Jun; 79(12):3116-29. PubMed ID: 1375841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
    Ghetie V; Engert A; Schnell R; Vitetta ES
    Cancer Lett; 1995 Nov; 98(1):97-101. PubMed ID: 8529213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia.
    Herrera L; Bostrom B; Gore L; Sandler E; Lew G; Schlegel PG; Aquino V; Ghetie V; Vitetta ES; Schindler J
    J Pediatr Hematol Oncol; 2009 Dec; 31(12):936-41. PubMed ID: 19875969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
    Cheng WW; Allen TM
    J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
    Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins.
    May RD; Vitetta ES; Moldenhauer G; Dörken B
    Cancer Drug Deliv; 1986; 3(4):261-72. PubMed ID: 2436739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin.
    Roy DC; Perreault C; Bélanger R; Gyger M; Le Houillier C; Blättler WA; Lambert JM; Ritz J
    J Clin Immunol; 1995 Jan; 15(1):51-7. PubMed ID: 7539011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.